Sensing Cancer on a Nanoscale Level
Cellens is a Boston-based Tufts University spinout pioneering a non-invasive cancer diagnostics platform that uses nanoscale mechanobiology and machine learning to detect bladder cancer from urine samples. Its Octosense platform scans cell surfaces at nanoscale resolution to identify unique biophysical fingerprints of cancer cells. The company raised a $6.5M seed round in December 2025 to advance its AI-driven diagnostic technology.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
